ISG had been working on the £300m scheme since 2019 with the building topping out in May 2023.

UCL said Mace was appointed “after a robust procurement and selection process” which “attracted a lot of interest from major contractors and all the bids were very strong.”

Mace will now carry out a detailed review of the job over the next three months before the terms of its appointment are finalised to complete the project at 256 Grays Inn Road.

UCL added: “UCL and Mace will continue to explore a potential role for incumbent suppliers formerly appointed by ISG during the review and delivery phases.”

Professor Alan Thompson, Dean, Faculty of Brain Sciences and Project Sponsor said: “I’m very pleased to welcome Mace to the programme. We felt very confident that the team shared our vision to build a world-class research and treatment centre, which will translate discoveries into treatments and have a real impact on patients with disabling neurological conditions.”

Robert Lemming, Managing Director, Public Sector and Life Sciences, Mace Construct added: “Following the successful completion of both UCL East Marshgate and the Student Centre, we are once again ready to partner with UCL on delivering this high-quality neuroscience building.

“We recognise the significance of this facility in advancing neurological research and treatment, and we are committed to ensuring its successful completion.”

The facility will be home to the UCL Queen Square Institute of Neurology; the UK Dementia Research Institute at UCL Centre and HQ (UK DRI) and an outpatient unit for the UCLH National Hospital for Neurology and Neurosurgery.